Day: April 28, 2021

WABASH, Ind., April 28, 2021 (GLOBE NEWSWIRE) — FFW Corporation (the “Corporation”) (OTC PINK: FFWC) (4/27/2021 Close: $43.00), parent corporation of Crossroads Bank (the “Bank”), announced earnings for the quarter and year to date ended March 31, 2021. For the three months ended March 31, 2021, the Corporation reported net income of $1,575,000 or $1.38 per common share compared to $1,109,000 or $0.98 per common share for the three months ended March 31, 2020. Net interest income for the three months ended March 31, 2021 was $3,655,000 compared to $3,639,000 for the three months ended March 31, 2020. The provision for loan losses was $165,000 for the three months ended March 31, 2021 and $75,000 for the three months ended March 31, 2020. Total noninterest income was $1,917,000 for the three months ended March 31, 2021 compared...

Updated Lifileucel Data from Cohort 2 in C-144-01 Clinical Study Initial Data for Lifileucel in Combination with Pembrolizumab in Immune Checkpoint Inhibitor Naïve Advanced Melanoma Cohort 1A in IOV-COM-202 Clinical Study SAN CARLOS, Calif., April 28, 2021 (GLOBE NEWSWIRE) — Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies (tumor-infiltrating lymphocyte, TIL, and peripheral-blood lymphocyte, PBL), today announced that clinical data for lifileucel alone and in combination with pembrolizumab for advanced melanoma will be highlighted at the upcoming ASCO 2021 Annual Meeting, to be held June 4-8, 2021. The abstract titles are as follows: Title: Lifileucel (LN-144), a cryopreserved autologous tumor infiltrating lymphocyte (TIL) therapy in patients with...

Initial pharmacokinetic (PK), safety, and preliminary efficacy data from Phase 1 dose-escalation portion of MasterKey-01 clinical trial to be presented CAMBRIDGE, Mass. and NEW YORK, April 28, 2021 (GLOBE NEWSWIRE) — Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a precision oncology medicine company pioneering the discovery and development of small molecule, MasterKey therapies, today announced that initial PK, safety, and preliminary efficacy data from the Phase 1 dose-escalation portion of the MasterKey-01 trial of BDTX-189 in patients with advanced solid tumors will be presented at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place June 4-8, 2021. Presentation details are as follows: Title: Safety and Preliminary Efficacy from the Phase 1 Portion of MasterKey-01: A First-in-Human Dose-Escalation...

Accomplished Regulatory Leader Joins MiMedx Management Team MARIETTA, Ga., April 28, 2021 (GLOBE NEWSWIRE) — MiMedx Group, Inc. (Nasdaq: MDXG) (“MiMedx” or “the Company”), an industry leader in utilizing amniotic tissue as a platform for regenerative medicine, today announced the addition of Dirk Stevens, Ph.D., as Senior Vice President, Quality Assurance and Regulatory Affairs, effective May 3, 2021. Dr. Stevens, who brings more than 35 years of strategic leadership experience in quality management and regulatory compliance across multiple medical device and pharmaceutical companies, joins MiMedx from Smith & Nephew, plc, where he was accountable for regulatory submissions, compliance, and Commercial Quality Assurance. Timothy R. Wright, MiMedx Chief Executive Officer, commented, “Over the past two years, we have assembled...

SYDNEY, Australia, April 28, 2021 (GLOBE NEWSWIRE) — Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), the leading developer of LAG-3 related immunotherapy treatments for cancer and autoimmune disease, is pleased to announce that new data from its TACTI-002 and INSIGHT-004 studies are scheduled to be presented in three poster presentations during the American Society of Clinical Oncology’s (ASCO) 2021 Annual Meeting, which is taking place online as a virtual meeting this year from 4 – 8 June. Abstracts will be available from 5pm US Eastern Time on 19 May 2021. Poster presentations with new and updated data that are not part of the abstract will be released on ASCO.org at the times indicated below and will subsequently be made available on Immutep’s website at www.immutep.com. In addition, Immutep plans...

Harvia Plc press release April 28, 2021 at 5:00 P.M. EETHarvia will publish its Interim Report for the period of January−March 2021 on Wednesday, May 5, 2021 at around 09:00 a.m. Finnish time. The stock exchange release and the presentation material will be available after publishing at https://harviagroup.com/investor-relations/. Harvia will hold a webcast for analysts, investors and media on May 5, 2021 at 11:00 a.m. EET. The conference will be held in English. Harvia’s CEO Tapio Pajuharju and CFO Ari Vesterinen will host the event. The webcast can be followed at https://harvia.videosync.fi/2021-q1-results You can also participate in the conference by calling: Finland: +358 981 710 310 Sweden: +46 856 642 651 UK: +44 333 300 0804 US: +1 631 913 1422 PIN: 85857878# A recording of the webcast will be available later at the company’s...

Ársreikningur Múlaþings fyrir árið 2020 lagður fram til fyrri umræðu í sveitarstjórn Múlaþings þann 28 apríl 2021 samþykktur og áritaður af byggðaráði og sveitarstjóra.  Samkvæmt sveitarstjórnarlögum skal fjalla um ársreikninginn á tveimur fundum í sveitarstjórn og er áætlað að síðari umræða fari fram miðvikudaginn 12. maí 2021. Sveitarfélagið Múlaþing varð til þann 1. október 2020 með sameiningu sveitarfélaganna Fljótsdalshéraðs, Seyðisfjarðarkaupstaðar, Djúpavogshrepps og Borgarfjarðarhrepps.Helstu niðurstöður:Rekstarafkoma Múlaþings árið 2020 var neikvæð um 110 millj. kr. samkvæmt samstæðureikningi sveitarfélagsins en samanlagðar fjárhagsáætlanir sveitarfélaganna 2020 með viðaukum gerði ráð fyrir 215 millj. kr. rekstrarafgangi.  Rekstrarafkoma A hluta var neikvæð um 172 millj. kr. en samanlagðar fjárhagsáætlanir með viðaukum gerði...

The annual general meeting of Hexagon Composites ASA was held today, Wednesday 28 April 2021 in Aalesund, Norway. All proposals on the agenda were adopted, cf. the notice of the annual general meeting that was sent to the Oslo Stock Exchange and shareholders on 7 April 2021. The complete minutes of the annual general meeting are attached to this release and are also available on www.hexagongroup.com.For more information:Hiva Ghiri, VP IR, Hexagon Composites ASATelephone: +47 958 66 790 | hiva.ghiri@hexagongroup.comAbout Hexagon Composites ASAHexagon delivers safe and innovative solutions for a cleaner energy future. Our solutions enable storage, transportation and conversion to clean energy in a wide range of mobility, industrial and consumer applications. Learn more at www.hexagongroup.com and follow @HexagonASA on Twitter and LinkedIn. This...

Resolutions of the Annual General Meeting of Tulikivi Corporation on 28 April 2021 The Annual General Meeting of Tulikivi Corporation was held through exceptional procedures on 28 April 2021 in Helsinki, Finland in accordance with the temporary legislative act to limit the spread of the Covid-19 pandemic (677/2020), which entered into force on 3 October 2020. The Company’s shareholders and their proxy representatives were able to participate in the General Meeting and exercise their shareholder rights only through voting in advance as well as by making counterproposals and presenting questions in advance. It was not possible to participate in the meeting in person at the meeting venue. The Annual General Meeting approved the financial statements for the financial year 2020 and discharged the members of the Board and the Managing Director...

RESEARCH TRIANGLE PARK, N.C., April 28, 2021 (GLOBE NEWSWIRE) — G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, will host a webcast and conference call to provide a corporate and financial update for the first quarter of 2021 on Wednesday, May 5, 2021 at 4:30 p.m. ET. The live call may be accessed by dialing (866) 763-6020 (domestic) or (210) 874-7713 (international) and entering the conference code: 2509548. The live and archived webcast will be available on the Events & Presentations page of http://www.g1therapeutics.com. About G1 TherapeuticsG1 Therapeutics, Inc. is a commercial-stage biopharmaceutical company focused on the discovery, development and delivery of next generation therapies that improve the lives of those affected by cancer, including the Company’s first commercial product, COSELA™...